CSIMarket Company Name, Ticker, Customers, else..
 
Tela Bio Inc   (NASDAQ: TELA)
 
Price: $0.8880 $-0.02 -1.878%
Day's High: $0.9187999963760376 Week Perf: 8.03 %
Day's Low: $ 0.88 30 Day Perf: 23.33 %
Volume (M): 73,595 52 Wk High: $ 1.70
Volume (M$): $ 0 52 Wk Avg: $0.97
Open: $0.89 52 Wk Low: $0.50



 Market Capitalization (Millions $) 51
 Shares Outstanding (Millions) 57
 Employees 218
 Revenues (TTM) (Millions $) 81
 Net Income (TTM) (Millions $) -41
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 0

Business Description


Tela Bio Inc is a medical technology company that specializes in the development and commercialization of tissue engineering products for surgical reconstruction of soft tissue defects. The company focuses on creating advanced and innovative products that improve patient outcomes and surgical techniques. Tela Bio's products are made from a proprietary material called OviTex, which combines biologic and synthetic components to optimize integration, strength, and compatibility with the body. The company's solutions are used in various surgical procedures, including hernia repair, abdominal wall reconstruction, and plastic/reconstructive surgery. Tela Bio Inc aims to provide surgeons with advanced tools to deliver better patient care and improve the quality of life for surgical patients.


   Company Address: 1 Great Valley Parkway, Suite 24 Malvern 19355 PA
   Company Phone Number: 320-2930   Stock Exchange / Ticker: NASDAQ TELA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
EW   -5.11%    
IART   -5.29%    
ISRG   -0.38%    
MDT   -2.35%    
SYK   -12.49%    
ZBH   -6.52%    
• View Complete Report
   



Shares

TELA Bio Expands Workforce with Strategic Inducement Grants Amid Growth in Medical Technology,

Published Fri, May 9 2025 8:05 PM UTC

Malvern, Pa. As part of its ongoing strategy to attract top talent and foster growth, TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company dedicated to advancing soft-tissue reconstruction solutions, has announced a series of inducement grants to newly hired employees under the Nasdaq Listing Rule 5635(c)(4). This recent development marks the third ...
Product Service News

Expanding Horizons in Reconstructive Surgery TELA Bios Launch of Larger OviTex PRS Sets New Industry Standard,

Published Mon, Mar 31 2025 12:04 PM UTC

Revolutionizing Reconstructive Surgery: TELA Bio Launches Larger OviTex PRS Options, Outshining the Competition In the ever-evolving world of medical technology, innovation isn’t just a buzzword; it’s a necessity. TELA Bio Inc. is stepping up to meet this demand head-on with the announcement of the U.S. commercial launch of larger sizes of its OviTex PRS product, a power...
Shares

TELA Bio Strengthens Workforce with Inducement Grants: Implications for Shareholders and Market Position

Published Fri, Jan 24 2025 9:05 PM UTC

In a strategic move to enhance its operational capacity, TELA Bio, Inc. (NASDAQ: TELA) announced on January 24, 2025, the approval of inducement grants covering 4,000 shares of its common stock to seven newly-hired employees, as sanctioned by the firm s Compensation Committee. This grants package, effective from January 21, 2025, is part of the company s ongoing commitment t...
Shares

TELA Bio Strengthens Workforce with Inducement Grants: Assessing the Impact on Company Shares

Published Fri, Feb 21 2025 9:05 PM UTC

In a significant move to bolster its team, TELA Bio, Inc. (NASDAQ: TELA), a leading commercial-stage medical technology firm specializing in innovative soft-tissue reconstruction solutions, has disclosed the approval of inducement grants. These grants were made under the Nasdaq Rule 5635(c)(4), designed to attract highly skilled talent to the company. Press Release DetailsO...
Stock Market Announcement

Investing in Talent: How TELA Bios Inducement Grants Signal Strategic Growth,

Published Fri, Dec 13 2024 9:05 PM UTC

TELA Bio: Strategic Inducement Grants and What They Mean for InvestorsIn a market where talent acquisition can dramatically shape the future trajectory of a company, TELA Bio, Inc. is taking significant steps to bolster its workforce by providing inducement grants to newly-hired employees. On December 13, 2024, TELA Bio, a commercial-stage medical technology company focused...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 0.63
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.59
Working Capital Ratio 2.86
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.79 $
Revenues (TTM) 1.4 $
Cash Flow (TTM) 0.08 $
Cash 0.53 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 369,427
Net Income per Employee (TTM) -188,894
Receivable Turnover Ratio (TTM) 7.86
Inventory Turnover Ratio (TTM) 2.3
Asset Turnover Ratio (TTM) 1.18

Profitability Ratios Current
Gross Margin (MRQ) 72.28 %
Operating Margin (MRQ) -48.12 %
Net Margin (MRQ) -58.38 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Tela Bio Inc's Segments
Single reportable segment    198.8 % of total Revenue
Non Us    38.88 % of total Revenue
US    159.66 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.